drugset / Trial / NCT03186638
Low-Dose Ibuprofen in Improving Cognitive Impairment in Patients With Cancer
Phase 2
Completed
87 enrolled
University of Rochester NCORP Research Base
National Cancer Institute (NCI) · collab
RandomizedParallel-groupDouble-blindSupportive care
Summary
This randomized phase II trial studies how well low-dose ibuprofen in improving cognitive impairment in patients with cancer. Anti-inflammatory agents, such as ibuprofen, may slow the decline of cognitive processes and diseases involving the brain.
Timeline
- Start
- 2017-05-26
- Primary completion
- 2022-03-30
- Completion
- 2022-06-01
Outcome
Missed primary endpoint
registry analysis (superiority test); Ibuprofen 200 mg BID vs Placebo; p = 0.7917; ANCOVA NCT03186638 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibuprofen | Small molecule | — | Oral |